Keyword: United Therapeutics

12. Remodulin

For a smaller pharma company like United Therapeutics, losing patent protection on a big drug is especially painful. Remodulin, approved in 2002, loses exclusivity this summer, meaning the company will soon face off against cheap competition to its biggest top-line contributor.